Chemotherapy-Associated Hepatotoxicities

Surgical Clinics of North America

Volumn 96, Issue 2, 2016, Pages 207-217

  White, Michael A ^a   Fong, Yuman ^a   Singh, Gagandeep ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Hepatectomy; Liver injury; Sinusoidal obstruction syndrome; Steatohepatitis; Steatosis

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ABLATION THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FATTY LIVER; HISTOPATHOLOGY; HUMAN; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; DRUG-INDUCED LIVER INJURY;

ANTINEOPLASTIC AGENTS; DRUG-INDUCED LIVER INJURY; HUMANS;

EID: 84961589511     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2015.11.005     Document Type: Review

References (29)

1. Fong Y., Bentrem D.J. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 2006, 243(1):8-9.
2. Dyson J.K., McPherson S., Anstee Q.M. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013, 66(12):1033-1045.
3. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
4. Maor Y., Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol 2013, 2013:815105.
5. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004, 15(3):460-466.
6. DeSantis C.E., Lin C.C., Mariotto A.B., et al. Cancer treatment and survivorship statistics, 2014. Cancer J Clinicians 2014, 64(4):252-271.
7. Donadon M., Ribero D., Morris-Stiff G., et al. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 2007, 1(1):20-27.
8. Figueras J., Torras J., Valls C., et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum 2007, 50(4):478-488.
9. Adam R., Miller R., Pitombo M., et al. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin North America 2007, 16(3):525-536. viii.
10. Fong Y. Chemotherapy and resection for colorectal metastases. Lancet Oncol 2013, 14(12):1148-1149.
11. Pawlik T.M., Olino K., Gleisner A.L., et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007, 11(7):860-868.
12. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24(13):2065-2072.
13. Tamandl D., Klinger M., Eipeldauer S., et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 2011, 18(2):421-430.
14. Laurent A., Nicco C., Tran Van Nhieu J., et al. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology 2004, 39(5):1277-1285.
15. Pessayre D., Berson A., Fromenty B., et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001, 21(1):57-69.
16. Cho C.S., Curran S., Schwartz L.H., et al. Preoperative radiographic assessment of hepatic steatosis with histologic correlation. J Am Coll Surgeons 2008, 206(3):480-488.
17. Vigano L., Capussotti L., De Rosa G., et al. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 2013, 258(5):731-740. [discussion: 41-2].
18. Parkin E., O'Reilly D.A., Adam R., et al. The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy. HPB 2013, 15(6):463-472.
19. Reddy S.K., Reilly C., Zhan M., et al. Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis. Med Oncol 2014, 31(6):971.
20. Parkin E., O'Reilly D.A., Adam R., et al. Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy. Eur J Surg Oncol 2014, 40(11):1436-1444.
21. Wolf P.S., Park J.O., Bao F., et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J Am Coll Surgeons 2013, 216(1):41-49.
22. Nakano H., Oussoultzoglou E., Rosso E., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008, 247(1):118-124.
23. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006, 24(31):4983-4990.
24. Kopetz S., Vauthey J.N. Perioperative chemotherapy for resectable hepatic metastases. Lancet 2008, 371(9617):963-965.
25. Welsh F.K., Tilney H.S., Tekkis P.P., et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007, 96(7):1037-1042.
26. Ferrero A., Vigano L., Polastri R., et al. Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. World J Surg 2007, 31(8):1643-1651.
27. Evrard S., Poston G., Kissmeyer-Nielsen P., et al. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One 2014, 9(12):e114404.
28. Rubbia-Brandt L., Lauwers G.Y., Wang H., et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010, 56(4):430-439.
29. van der Pool A.E., Marsman H.A., Verheij J., et al. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. J Surg Oncol 2012, 106(7):892-897.